Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 3:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 4,589 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Crossover Clear all
Not listed Not applicable Interventional Results available

Feasibility Study of ExAblate Thalamotomy for Treatment of Chronic Trigeminal Neuropathic Pain

NCT03309813
View directory record Official record
Conditions
Trigeminal Neuropathic Pain
Interventions
Transcranial ExAblate, Sham Transcranial ExAblate, Crossover Transcranial Exablate
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 25, 2026, 3:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

Disulfiram for Treatment of Retinal Degeneration

NCT05626920
View directory record Official record
Conditions
Inherited Retinal Dystrophy Primarily Involving Sensory Retina
Interventions
Disulfiram 250 mg, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 25, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)

NCT04270682
View directory record Official record
Conditions
CTX
Interventions
Blinded CDCA 250 mg TID, Placebo, Open-Label CDCA 250 mg TID, Rescue Medication CDCA 250 mg TID, CDCA Weight-Based Dose TID
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
1 Month and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
9
States / cities
Aurora, Colorado • Orlando, Florida • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 25, 2026, 3:32 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions

NCT06494397
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder
Interventions
VHX-896 and iloperidone, Iloperidone and VHX-896
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Los Alamitos, California • Gaithersburg, Maryland • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 25, 2026, 3:32 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Telerehabilitation Alzheimer's Disease Feasibility (TADF)

NCT04732182
View directory record Official record
Conditions
Alzheimer Disease, Healthy Aging
Interventions
BrightGo cognitive training, Standard of Care medication for early Alzheimer's Disease
Device · Drug
Lead sponsor
Bright Cloud International Corp
Industry
Eligibility
65 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
New Brunswick, New Jersey • North Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 25, 2026, 3:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CSD190102: A Study to Assess Nicotine Pharmacokinetic Parameters After Use of Two Smokeless Tobacco Products

NCT03993782
View directory record Official record
Conditions
Tobacco Use
Interventions
A19010-R, B19010-O
Other
Lead sponsor
RAI Services Company
Industry
Eligibility
21 Years to 60 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
6
States / cities
Rogers, Arkansas • Lexington, Kentucky • Springfield, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2019 · Synced Oct 25, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT03628924
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Guselkumab dose 1, Guselkumab dose 2, Guselkumab dose 3, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
Birmingham, Alabama • Largo, Florida • Ocala, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 25, 2026, 3:32 AM EDT
Completed Phase 4 Interventional Results available

A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study

NCT03687827
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin degludec, Insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
34
States / cities
Chandler, Arizona • Tucson, Arizona • Fresno, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 25, 2026, 3:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

IceBath: NOICE vs Nothing

NCT07227142
View directory record Official record
Conditions
Pain
Interventions
Non-visual immersive technology-based audio biofeedback intervention, Control (No non-visual immersive technology-based audio biofeedback)
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 99 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 25, 2026, 3:32 AM EDT
Completed Phase 4 Interventional

Evaluation of the Safety Use of the InsuPatch Device in Daily Life Conditions

NCT01283425
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
InsuPatch
Device
Lead sponsor
Insuline Medical Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Oct 25, 2026, 3:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

How do You Take Your Coffee Before Anesthesia

NCT04786691
View directory record Official record
Conditions
Anesthesia, Aspiration, Fasting
Interventions
Addition of half and half to coffee, Addition of non-dairy creamer to coffee, Black
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 25, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus

NCT02954601
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
ORMD-0801 (qd), ORMD-0801 (bid), ORMD-0801 (tid), Placebo
Drug · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
20 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 25, 2026, 3:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects

NCT01475981
View directory record Official record
Conditions
Healthy
Interventions
JTK-853 or Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Oct 25, 2026, 3:32 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

NCT05662319
View directory record Official record
Conditions
Hemophilia
Interventions
Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older · Male only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
8
States / cities
Orange, California • Minneapolis, Minnesota • Hackensack, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 25, 2026, 3:32 AM EDT
Completed Phase 1 Interventional

Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsules

NCT01170975
View directory record Official record
Conditions
Solid Tumors
Interventions
Tesetaxel 10 mg with and then without food, Tesetaxel 10 mg without and then with food
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Oct 25, 2026, 3:32 AM EDT
Completed Phase 2 Interventional

A Study To Investigate Whether PF-04457845 Is Effective In Treating Pain, Is Safe And Tolerable In Patients With Osteoarthritis Of The Knee

NCT00981357
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
PF-04457845, Naproxen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Miami, Florida • Overland Park, Kansas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 25, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler

NCT04027439
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Part A: RPL554, Part B: RPL554, Placebos
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Union, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 25, 2026, 3:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating BLI-489 and Piperacillin in Healthy Subjects

NCT00894439
View directory record Official record
Conditions
Healthy Subjects
Interventions
BLI-489/Piperacillin, BLI-489, Piperacillin
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2009 · Synced Oct 25, 2026, 3:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants

NCT05615012
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986322, Rosuvastatin, Metformin, Glucose, Methotrexate, Leucovorin
Drug · Dietary Supplement
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 25, 2026, 3:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants

NCT05654181
View directory record Official record
Conditions
Healthy
Interventions
PF-07328948, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 25, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age

NCT05169905
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT vaccine, dTpa vaccine
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
9 Years to 49 Years · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Beaumont, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 25, 2026, 3:32 AM EDT
Not listed Phase 4 Interventional

Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension

NCT01468571
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 25, 2026, 3:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

NCT03363893
View directory record Official record
Conditions
Advanced Solid Malignancies
Interventions
CT7001, Fulvestrant
Drug
Lead sponsor
Carrick Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
12
States / cities
Tucson, Arizona • Beverly Hills, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 25, 2026, 3:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fasted Conditions

NCT01367652
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 25, 2026, 3:32 AM EDT